Acquired TSC1 Mutation as a Mechanism of Alectinib Resistance in ALK -Fused Leiomyosarcoma: Response to Combined ALK and Mammalian Target of Rapamycin Inhibition
- 1 July 2026
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600046
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancerMolecular Oncology, 2025
- BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancerLung Cancer, 2020
- Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical SequencingClinical Cancer Research, 2020
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue SarcomasCell, 2017
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2Annals of Oncology, 2014
- A panel of antibodies to determine site of origin and malignancy in smooth muscle tumorsLaboratory Investigation, 2009
- Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroupsCancer, 2009
- Prognostic factors and survival in 1396 patients with uterine leiomyosarcomasCancer, 2008
- Inflammatory Myofibroblastic TumorAmerican Journal of Surgical Pathology, 2007
- Problematic Uterine Smooth Muscle NeoplasmsAmerican Journal of Surgical Pathology, 1994